Kdy ukončit léčbu hepatitidy B?
| Title in English | Current view on hepatitis B diagnosis and therapy |
|---|---|
| Authors | |
| Year of publication | 2021 |
| Type | Article in Periodical |
| Magazine / Source | Vnitřní lékařství |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.casopisvnitrnilekarstvi.cz/artkey/vnl-202101-0007_current-view-on-hepatitis-b-diagnosis-and-therapy.php?back=%2Fsearch.php%3Fquery%3D%2509Kdy%2Bukon%25E8it%2Bl%25E9%25E8bu%2Bhepatitidy%2BB%253F%26sfrom%3D0%26spage%3D30 |
| Doi | http://dx.doi.org/10.36290/vnl.2021.007 |
| Keywords | chronic hepatitis B; tenofovir; entecavir; stopping therapy |
| Description | Hepatitis B virus (HBV) infection remains a global public health problem with changing epidemiology due to several factors predominantly vaccination policy and migration. Chronic hepatitis B is a dynamic process reflecting the interaction between HBV replication and the host immune response and not all patients with chronic HBV infection have chronic hepatitis B. Stopping of nucleotide or nucleoside analogues (NA) therapy is a serious resolution due the danger of reactivation of viral replication associated with increasing HBV DNA level, ALT activity and inflammatory activity in the liver histology. The safest stopping rule for NA therapy is HBsAg loss what is the sign of immune control of HBV infection. |